Takeda Sees Strong Fundamentals Despite Post-Shire Loss Outlook

Post-Shire Takeda expects losses in its first annual forecast for the combined business, plus "significant headwinds" from expected Velcade erosion. But underlying new and legacy Takeda business is seen remaining strong.

Takeda Tokyo HQ entrance
Shire Deal To Move Takeda Into Large Annual Loss • Source: Takeda

In its first full fiscal year outlook since completing the $62bn acquisition of Shire PLC in early January, Takeda Pharmaceutical Co. Ltd. expects the newly merged business to achieve "flat to slightly declining" underlying revenue growth, affected in part by increased US generic competition to one of its top products.

A mid-twenties percentage increase in underlying core earnings margin is foreseen, while underlying core EPS should be in the JPY350-370...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By 

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.